GSK: reports positive data on respiratory vaccines

(CercleFinance.com) - GlaxoSmithKline disclosed on Wednesday positive clinical data for two candidate vaccines against respiratory syncytial virus, or RSV.


The British drugmaker said that phase I/II data showed that the two experimental vaccines triggered robust immune response in the studies, and were tolerated well.

There is currently no vaccine for respiratory syncytial virus (RSV), which causes infections such as bronchiolitis in todlers and pneumonia in older adults.

RSV is estimated to cause about 3 million hospitalisations of children under 5 years old globally, and 177,000 hospitalisations of older people in the US alone.

Phase III studies in both older adults and infants are being prepared and are scheduled to start in the coming months, GSK said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.